SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ — United Therapeutics Corporation (UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020.

source https://finance.yahoo.com/news/united-therapeutics-announces-fda-acceptance-100000113.html?.tsrc=rss